Off-highway tyremaker Balkrishna Industries Ltd. expects a tough road ahead.
Sun Pharma received the first drug approval in five years for its key Halol plant.
Shares of UPL have fallen ever since reports of its proposed Arysta LifeScience buyout came out.
The revised axle weight of each type was notified by the Ministry of Road Transport and Highways yesterday.
Dr. Reddy’s will not be able to sell or export generic Suboxone until the outcome of the patent litigation.
Brokerages expect a low base due to GST-led destocking and demonetisation to boost the June quarter earnings.
Here are the five stocks that Nomura says can give returns between 18-28 percent over the next one year.
Zee has a 25 percent viewership share across network, while Star India has 24 percent, BARC data show.
CLSA said it prefers structural long-term themes such as housing, building materials and healthcare.
The 10-year bond yields, which are hovering around 8 percent, are unlikely to cool off.
Will Dr Reddy’s launch opioid addiction drug’s generic despite the risks?
U.S. regulator clears Sun Pharma’s Halol unit as it resolves all issues.
In a major relief to Sun Pharma, U.S. FDA issued a ‘voluntary action indicated’ status to its Halol plant.
Fulphila is the second biosimilar developed by the Biocon to get an approval from the U.S. drug regulator
18 out of Nifty 50 Firms surpassed street forecast in March quarter, the highest in a year.
Exports should be largely in line with global GDP with growth range being 0-5 percent: Cummins India management.
Of the six pharma majors, Sun Pharma and Cadila Healthcare were the only two to report operating margins over 20%.
The resignation comes just days before the company’s board meeting to announce March quarter results on May 30.
Mid-cap valuations remain expensive despite the recent correction.
The outcome of today’s Fortis EGM will have a bearing on who takes over India’s second-largest hospital chain.
The observations appear benign with no data integrity issues and mainly pertain to quality and controls.